Nivolumab (Opdivo®) for metastatic DNA mismatch repair-deficient (dMMR) or microsatellite instability-high (MSI-H) colorectal cancer (CRC)
Grössmann N
Record ID 32018000198
English
Authors' recommendations:
The treatment of nivolumab offers durable responses, 31.1% demonstrated partial responses with an acceptable safety profile at high costs. However, the immature OS data in combination with the lack of evidence for the actual patient population affected most by CRC in clinical practice highlight the requirement for long-term data. Moreover, head-to-head comparisons will be necessary to identify the best treatment option for CRC patients with dMMR/MSI-H. Ultimately, trustworthy biomarker testing will be needed to select those patients who benefit most from nivolumab.
Details
Project Status:
Completed
URL for project:
https://hta.lbg.ac.at/page/horizon-scanning-in-der-onkologie/en
Year Published:
2017
URL for published report:
n/a
URL for additional information:
http://eprints.hta.lbg.ac.at/1144/
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Austria
MeSH Terms
- Antibodies, Monoclonal
- Colonic Neoplasms
- Colorectal Neoplasms
- DNA Mismatch Repair
- Diagnostic Tests, Routine
- Antineoplastic Agents, Immunological
- Microsatellite Instability
- Nivolumab
- Antibodies, Monoclonal, Humanized
- Immune Checkpoint Inhibitors
Contact
Organisation Name:
Ludwig Boltzmann Institute for Health Technology Assessment
Contact Address:
Ludwig Boltzmann Institute for fuer Health Technology Assessment (LBI-HTA), Garnisongasse 7/rechte Stiege Mezzanin (Top 20), 1090 Vienna, Austria. Tel: +43 1 236 8119 - 0 Fax: +43 1 236 8119 - 99
Contact Name:
tarquin.mittermayr@aihta.at
Contact Email:
office@aihta.at
Copyright:
Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.